Relationship between sputum bacterial load and lung function in children with cystic fibrosis receiving tobramycin

IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Respiratory medicine Pub Date : 2025-03-14 DOI:10.1016/j.rmed.2025.108042
Kiera Harwood , Stephen Duffull , Tony Lai , Alice Lei , Sarah Manning , Casey Pell , Sarath Ranganathan , Phil Robinson , Geraint Rogers , Indy Sandaradura , Catherine Satzke , Shivanthan Shanthikumar , Steven Taylor , Amanda Gwee
{"title":"Relationship between sputum bacterial load and lung function in children with cystic fibrosis receiving tobramycin","authors":"Kiera Harwood ,&nbsp;Stephen Duffull ,&nbsp;Tony Lai ,&nbsp;Alice Lei ,&nbsp;Sarah Manning ,&nbsp;Casey Pell ,&nbsp;Sarath Ranganathan ,&nbsp;Phil Robinson ,&nbsp;Geraint Rogers ,&nbsp;Indy Sandaradura ,&nbsp;Catherine Satzke ,&nbsp;Shivanthan Shanthikumar ,&nbsp;Steven Taylor ,&nbsp;Amanda Gwee","doi":"10.1016/j.rmed.2025.108042","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Chronic pulmonary infection with pathogens such as <em>Pseudomonas aeruginosa</em> is associated with lung function decline and increased mortality in people with cystic fibrosis (CF). The relationship between sputum bacterial load and the severity of pulmonary exacerbations remains unclear. This study aimed to explore the relationship between sputum bacterial load and clinical response to antibiotic treatment of pulmonary exacerbations in children with CF.</div></div><div><h3>Methods</h3><div>Multicentre prospective longitudinal study of children with CF receiving IV tobramycin for a pulmonary exacerbation who had prior isolation of Gram-negative bacteria and able to expectorate sputum. Lung function (FEV<sub>1</sub>) and sputum bacterial load were assessed. Bacterial load was performed using quantitative PCR on either intact (live) bacterial cells or all bacterial DNA (live + dead) and targeted either <em>P. aeruginosa</em> only or all bacteria.</div></div><div><h3>Results</h3><div>Twelve children (14 admissions) were enrolled and each provided ≥2 sputum samples; 11 children (13 admissions) also had ≥2 FEV<sub>1</sub> measurements. In 10 admissions where FEV<sub>1</sub> improved, five showed a reduction in all live bacteria, with a median reduction by 8.65 × 10<sup>6</sup> copies/g (73 % reduction). Live <em>P. aeruginosa</em> was detected in 8/10 children and in seven, a median reduction of 2.99 × 10<sup>7</sup> copies/g (90 % reduction) was observed. Improved FEV<sub>1</sub> correlated with greater reductions in live + dead <em>P. aeruginosa</em> (ρ = −0.63, p = 0.04).</div></div><div><h3>Conclusion</h3><div>A greater reduction in total sputum <em>P. aeruginosa</em> bacterial load (live + dead) was associated with improved lung function (FEV<sub>1</sub>) in children with CF receiving tobramycin.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"240 ","pages":"Article 108042"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611125001040","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Chronic pulmonary infection with pathogens such as Pseudomonas aeruginosa is associated with lung function decline and increased mortality in people with cystic fibrosis (CF). The relationship between sputum bacterial load and the severity of pulmonary exacerbations remains unclear. This study aimed to explore the relationship between sputum bacterial load and clinical response to antibiotic treatment of pulmonary exacerbations in children with CF.

Methods

Multicentre prospective longitudinal study of children with CF receiving IV tobramycin for a pulmonary exacerbation who had prior isolation of Gram-negative bacteria and able to expectorate sputum. Lung function (FEV1) and sputum bacterial load were assessed. Bacterial load was performed using quantitative PCR on either intact (live) bacterial cells or all bacterial DNA (live + dead) and targeted either P. aeruginosa only or all bacteria.

Results

Twelve children (14 admissions) were enrolled and each provided ≥2 sputum samples; 11 children (13 admissions) also had ≥2 FEV1 measurements. In 10 admissions where FEV1 improved, five showed a reduction in all live bacteria, with a median reduction by 8.65 × 106 copies/g (73 % reduction). Live P. aeruginosa was detected in 8/10 children and in seven, a median reduction of 2.99 × 107 copies/g (90 % reduction) was observed. Improved FEV1 correlated with greater reductions in live + dead P. aeruginosa (ρ = −0.63, p = 0.04).

Conclusion

A greater reduction in total sputum P. aeruginosa bacterial load (live + dead) was associated with improved lung function (FEV1) in children with CF receiving tobramycin.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受妥布霉素治疗的囊性纤维化患儿痰液细菌负荷与肺功能的关系
背景:慢性肺部感染病原体如铜绿假单胞菌与囊性纤维化(CF)患者肺功能下降和死亡率增加有关。痰细菌负荷与肺恶化严重程度之间的关系尚不清楚。本研究旨在探讨CF患儿痰液细菌负荷与抗生素治疗肺加重的临床反应之间的关系。方法:多中心前瞻性纵向研究CF患儿接受静脉妥布霉素治疗肺加重,既往革兰氏阴性菌分离,能够咳痰。评估肺功能(FEV1)和痰菌负荷。使用定量PCR对完整(活的)细菌细胞或所有细菌DNA(活的+死的)进行细菌负载,并仅针对铜绿假单胞菌或所有细菌。结果:纳入12名儿童(14名入院),每人提供≥2份痰液样本;11名儿童(13名入院)的FEV1测量值也≥2。在10例FEV1改善的入院患者中,5例显示所有活细菌减少,中位数减少8.65×106拷贝/克(减少73%)。在8/10名儿童中检测到活的铜绿假单胞菌,其中7名儿童观察到中位数减少2.99×107拷贝/g(减少90%)。FEV1的改善与活的和死的铜绿假单胞菌的减少相关(ρ = -0.63, p = 0.04)。结论:接受妥布霉素治疗的CF患儿肺功能(FEV1)的改善与痰中铜绿假单胞菌菌载量(活菌+死菌)的显著降低有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respiratory medicine
Respiratory medicine 医学-呼吸系统
CiteScore
7.50
自引率
0.00%
发文量
199
审稿时长
38 days
期刊介绍: Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.
期刊最新文献
Respiratory reactance index across severities of airflow obstruction in COPD and asthma. Real-world, long-term effectiveness of dupilumab treatment in patients with severe asthma: 2 years of the ProVENT study. Bronchiectasis: Past insights, present clinical evidence, and future research pathways. Differential diagnosis of severe reactions mimicking or related to allergy and hidden allergens. A decade of treatable traits in patients with COPD: lessons learned about its application.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1